US2014031321A1PendingUtilityA1

Method of inducing negative chemotaxis

38
Assignee: CELTAXSYS INCPriority: Oct 10, 2008Filed: Jan 14, 2013Published: Jan 30, 2014
Est. expiryOct 10, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Erica B. Goodhew
A61P 35/00A61P 29/00A61K 31/593A61K 31/513A61K 31/137A61K 31/55A61K 31/135A61K 31/4015A61K 31/506A61K 31/592A61K 31/40A61K 31/59A61K 31/192Y02A50/30A61K 31/122
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of inducing negative chemotaxis of a human migratory cell comprising administering an effective amount of a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof. 
     
     
         2 . The method of  claim 1 , wherein the human migratory cell is an immune cell. 
     
     
         3 . The method of  claim 2 , wherein the immune cell is selected from the group consisting of lymphocytes, monocytes, neutrophils, eosinophils, and mast cells. 
     
     
         4 . The method of  claim 3 , wherein the immune cell is a neutrophil. 
     
     
         5 . The method of  claim 3 , wherein the immune cell is an eosinophil. 
     
     
         6 . The method of  claim 1 , wherein the compound is idebenone. 
     
     
         7 . The method of  claim 1 , wherein the compound is benazepril. 
     
     
         8 . The method of  claim 7 , wherein the compound is benazepril hydrochloride. 
     
     
         9 . The method of  claim 1 , wherein the compound is rolipram. 
     
     
         10 . The method of  claim 1 , wherein the compound is moxonidine. 
     
     
         11 . The method of  claim 10 , wherein the compound is moxonidine hydrochloride. 
     
     
         12 . The method of  claim 1 , wherein the compound is lamivudine. 
     
     
         13 . The method of  claim 1 , wherein the compound is a Vitamin D analog. 
     
     
         14 . The method of  claim 13 , wherein the Vitamin D analog is selected from the group consisting of calcitriol, calcipotriol, ergocalciferol and cholecalciferol. 
     
     
         15 . The method of  claim 14 , wherein the Vitamin D analog is calcitriol. 
     
     
         16 . The method of  claim 1 , wherein the compound is loxoprofen. 
     
     
         17 . The method of  claim 16 , wherein the compound is loxoprofen sodium. 
     
     
         18 . The method of  claim 1 , wherein the compound is terbinafine. 
     
     
         19 . The method of  claim 18 , wherein the compound is terbinafine hydrochloride. 
     
     
         20 . The method of  claim 1 , wherein the compound is Synephrine. 
     
     
         21 . The method of  claim 1 , wherein the compound is 6-aminoindazole. 
     
     
         22 . The method of  claim 1 , wherein chemotaxis toward a site of inflammation is inhibited. 
     
     
         23 . The method of  claim 1 , wherein chemotaxis toward a medical implant is inhibited. 
     
     
         24 . The method of  claim 1 , wherein chemotaxis toward a site of angiogenesis is inhibited. 
     
     
         25 . A method of inhibiting the chemotactic induction of an immune cell in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof. 
     
     
         26 . The method of  claim 25 , wherein the patient is suffering from an inflammatory condition. 
     
     
         27 . The method of  claim 25 , wherein the compound is administered locally to the site of inflammation. 
     
     
         28 . The method of  claim 26 , wherein the inflammatory condition is injection site reaction. 
     
     
         29 . The method of  claim 25 , wherein the patient is suffering from cancer or a tumor and angiogenesis is inhibited. 
     
     
         30 . The method of  claim 25 , wherein chemotactic induction of an immune cell toward a medical implant is inhibited. 
     
     
         31 . The method of  claim 30 , wherein the compound is administered by coating a surface of the medical implant. 
     
     
         32 . The method of  claim 30 , wherein the compound is administered locally at the site of the medical implant. 
     
     
         33 . The method of  claim 25 , wherein chemotactic induction of an immune cell toward a transplant or graft is inhibited.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.